Barbara Weber - 08 Oct 2024 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Reporting relationship: Director
Issuer ticker: RVMD
Reported as of: 08 Oct 2024
Net transaction value: -$249,716
SEC form: 4
Accepted by SEC: 10 Oct 2024, 16:16:37 UTC
Prior SEC filing: 23 Aug 2024
Next SEC filing: 05 Feb 2025
Source filing: View source filing
Reporting owner signature: /s/ Jack Anders, as Attorney-in-fact for Barbara Weber

Key filing fact

Barbara Weber filed Form 4 for Revolution Medicines, Inc. (RVMD) on 10 Oct 2024.

Key facts

This page summarizes Barbara Weber's Form 4 filing for Revolution Medicines, Inc. (RVMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 10 Oct 2024, 16:16.

Change

Previous filing in this sequence was filed on 23 Aug 2024.
Current net transaction value: -$249,716.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RVMD transaction

Common Stock

Sale

Transaction value: $249,716
Shares: -5,200
Change %: -28%
Price: $48.02
Shares after: 13,065
Date: 08 Oct 2024
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 29, 2024.

Footnote F2

The transaction was executed in multiple trades in prices ranging from $48.00 to $48.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Footnote F3

Includes 4,248 restricted stock units.